載入中
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
前收盤價
US$4.00
US$0.00 · 0.00%
盤後
US$4.00
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
日內區間
目前US$4.00
52週區間
目前US$4.00
盤中時間採用ET。市場資料可能有所延遲。
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
日內區間
目前US$4.00
52週區間
目前US$4.00
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 4208.2萬 USD | 2440.1萬 USD | 4399.9萬 USD | 2368.9萬 USD | — |
| 銷售、一般及管理費用 | 3316.4萬 USD | 3078.8萬 USD | 1863.9萬 USD | 347.3萬 USD | 109.2萬 USD |
| 營業費用 | 7524.6萬 USD | 5518.9萬 USD | 6263.8萬 USD | 2716.2萬 USD | 109.2萬 USD |
| 利息收入 | 633.6萬 USD | 799.8萬 USD | 218.6萬 USD | 570 USD | 2.35萬 USD |
| 折舊和攤銷 | 4.9萬 USD | 9000 USD | — | — | — |
| 營業利益 | −7524.6萬 USD | −5518.9萬 USD | −6263.8萬 USD | −2716.2萬 USD | −109.2萬 USD |
| 淨利 | −6865萬 USD | −5240.3萬 USD | −6036萬 USD | −2573.8萬 USD | 841.67萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$20.00
上漲空間 400.00%報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM617.19萬0.01%787.4億 USD0.19%US$277.9—
Vanguard Extended Market ETFVXF418.76萬0.00%954億 USD0.05%US$233.52—
iShares Russell 2000 Growth ETFIWO220.6萬0.02%139.17億 USD0.24%US$353.71—
Vanguard Russell 2000 ETFVTWO187.58萬0.01%180億 USD0.06%US$112.27—
iShares Micro-Cap ETFIWC73.82萬0.06%13.17億 USD0.60%US$181.66—
ALPS Medical Breakthroughs ETFSBIO48.32萬0.26%——US$53.85—
Vanguard Russell 2000 Growth ETFVTWG35.46萬0.02%17億 USD0.06%US$258.28—
iShares Russell 2500 ETFSMMD13.09萬0.00%40.62億 USD0.23%US$86.01—iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
